Literature DB >> 33560383

Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions.

Sarah J Waldis1, Stacey Uter2, Donna Kavitsky3, Cynthia Flickinger3, Sunitha Vege4, David F Friedman2,5, Connie M Westhoff4, Stella T Chou2.   

Abstract

Chronically transfused patients with thalassemia are at risk for red cell alloimmunization. No studies have specifically examined alloimmunization after implementation of prophylactic Rh (D, C, E) and K matched red cells in a racially diverse population of thalassemia patients and donors. This retrospective study examined Rh antibodies among 40 chronically transfused patients (Asian, White, Black, Indian, Middle Eastern) with thalassemia receiving a mean of 174 serologic prophylactic RhD, C, E, and K matched red cell units. We examined the patients' RH genotype, as well as donor race and Rh phenotypes over 3 transfusion events preceding antibody detection. Eighteen alloantibodies were detected in 13 of 40 patients (32.5%), with an alloimmunization rate of 0.26 antibodies per 100 units transfused. Thirteen antibodies (72.2%) were directed against Rh (5 anti-D, 4 anti-C, 2 anti-E, 1 anti-e, 1 anti-V), despite donor phenotypes that confirmed lack of transfusion of D, C, or E antigens to patients lacking the corresponding antigen(s). Ten of 40 patients had an altered RH genotype, but the Rh antibodies were not associated with patients with variant RH. Black donors with a known high frequency of RH variants provided 63% of the units transfused in the 3 visits preceding unexplained anti-Rh detection. Rh alloimmunization not explained by the thalassemia patients' RH genotype or the donors' serologic phenotype suggests more precise matching is needed, and the role of donor RH genotypes on alloimmunization should be explored. Extending Rh D, C, and E matching to include c and e would result in better-matched units and further minimize Rh alloimmunization.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 33560383      PMCID: PMC7876880          DOI: 10.1182/bloodadvances.2020003732

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  16 in total

1.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

2.  Allosensitization in patients receiving multiple blood transfusions.

Authors:  V S Sakhalkar; K Roberts; L M Hawthorne; D M McCaskill; D M Veillon; G C Caldito; J D Cotelingam
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

3.  Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review.

Authors:  Massimo Franchini; Gian Luca Forni; Giuseppe Marano; Mario Cruciani; Carlo Mengoli; Valeria Pinto; Lucia De Franceschi; Donatella Venturelli; Maddalena Casale; Martina Amerini; Martina Capuzzo; Giuliano Grazzini; Francesca Masiello; Ilaria Pati; Eva Veropalumbo; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

4.  Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Authors:  Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

5.  The RHCE allele ceRT: D epitope 6 expression does not require D-specific amino acids.

Authors:  Franz F Wagner; Birgit Ladewig; Willy A Flegel
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

Review 6.  Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline.

Authors:  Veerle Compernolle; Stella T Chou; Susano Tanael; William Savage; Jo Howard; Cassandra D Josephson; Isaac Odame; Christopher Hogan; Gregory Denomme; Nadine Shehata
Journal:  Transfusion       Date:  2018-04-26       Impact factor: 3.157

Review 7.  Application of genomics for transfusion therapy in sickle cell anemia.

Authors:  Stella T Chou; Connie M Westhoff
Journal:  Blood Cells Mol Dis       Date:  2017-08-08       Impact factor: 3.039

8.  High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.

Authors:  Stella T Chou; Tannoa Jackson; Sunitha Vege; Kim Smith-Whitley; David F Friedman; Connie M Westhoff
Journal:  Blood       Date:  2013-05-30       Impact factor: 22.113

9.  RH genotype matching for transfusion support in sickle cell disease.

Authors:  Stella T Chou; Perry Evans; Sunitha Vege; Sarita L Coleman; David F Friedman; Margaret Keller; Connie M Westhoff
Journal:  Blood       Date:  2018-07-19       Impact factor: 22.113

10.  Alloimmunization screening after transfusion of red blood cells in a prospective study.

Authors:  Vitor Mendonça Alves; Paulo Roberto Juliano Martins; Sheila Soares; Gislene Araújo; Luciana Cayres Schmidt; Sidneia Sanches de Menezes Costa; Dante Mário Langhi; Helio Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2012
View more
  1 in total

Review 1.  Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.

Authors:  Yazan Migdady; Yifan Pang; Shelley S Kalsi; Richard Childs; Sally Arai
Journal:  Blood Adv       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.